MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma
Cell · 2025-08 · 188 (17) · 4622-4639.e19
DOI: 10.1016/j.cell.2025.05.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2025-08. Verfasst von Rajappa S Kenchappa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA. Electro…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Nonmuscle Myosin Type IIA, Nonmuscle Myosin Type IIB. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most lethal of primary brain tumors. Here, we report our studies of MT-125, a small-molecule inhibitor of non-muscle myosin II. MT-125 has high brain penetrance and an excellent safety profile, blocks GBM invasion and cytokinesis, and prolongs survival in murine GBM models. By impairing mitochondrial fission, MT-125 increases redox stress and consequent DNA damage, and it synergizes with radiotherapy. MT-125 also induces oncogene addiction to PDGFR signaling through a mechanism that is driven by redox stress, and it synergizes with FDA-approved PDGFR and mTOR inhibitors in vitro. Consistent with this, we find that combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor, significantly improves survival in orthotopic GBM models over either drug alone. Our results demonstrate that MT-125 is a first-in-class therapeutic that has strong clinical potential for the treatment of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA; Department of Neurosurgery, Mayo Clinic, Jacksonville, FL 32224, USA. Electronic address: kenchappa.rajappa@mayo.edu.
- Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Rese…
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA.
- Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Department of Chemical and Biological Engineering, University of Colorado, Boulder, Boulder, CO 80303, USA.
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- NIAMS NIH HHS
- NIAID NIH HHS
- NIDA NIH HHS
- NCRR NIH HHS
- National Institute on Drug Abuse
- Ben and Catherine Ivy Foundation
Zitieren
APA
Kenchappa, R. S., Radnai, L., Young, E. J., Zarco, N., Lin, L., Dovas, A., Meyer, C. T., Haddock, A., Hall, A., Toth, K., Canoll, P., Nagaiah, N. K. H., Rumbaugh, G., Cameron, M. D., Kamenecka, T. M., Griffin, P. R., Miller, C. A., & Rosenfeld, S. S. (2025). MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell, 188(17), 4622-4639.e19. https://doi.org/10.1016/j.cell.2025.05.019
Vancouver
Kenchappa RS, Radnai L, Young EJ, Zarco N, Lin L, Dovas A, et al. MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell. 2025;188(17):4622-4639.e19. doi:10.1016/j.cell.2025.05.019
BibTeX
@article{Kenchappa2025,
author = {Kenchappa, Rajappa S and Radnai, Laszlo and Young, Erica J and Zarco, Natanael and Lin, Li and Dovas, Athanassios and Meyer, Christian T and Haddock, Ashley and Hall, Alice and Toth, Katalin and Canoll, Peter and Nagaiah, Naveen K H and Rumbaugh, Gavin and Cameron, Michael D and Kamenecka, Theodore M and Griffin, Patrick R and Miller, Courtney A and Rosenfeld, Steven S},
title = {MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma},
journal = {Cell},
year = {2025},
volume = {188},
number = {17},
pages = {4622--4639.e19},
doi = {10.1016/j.cell.2025.05.019}
}
EUVIMED